RESUMO
OBJECTIVE: To evaluate the effectiveness and safety of cefovecin sodium in the treatment of cats with naturally occurring skin infections (abscesses and infected wounds). DESIGN: Multicenter (26 sites), randomized, double-blind, controlled clinical trial. ANIMALS: Client-owned cats of any breed with naturally occurring skin infections with associated clinical signs and confirmatory bacteriologic culture results. PROCEDURES: Cats with clinical signs of skin and soft tissue infection were randomly allocated to receive a single dose of cefovecin (8 mg/kg [3.6 mg/lb], SC) followed by placebo drops administered orally once daily for 14 days or 1 SC placebo injection followed by cefadroxil (22 mg/kg [10 mg/lb], PO, once daily for 14 days). Only one 14-day treatment course was permitted. RESULTS: Effectiveness of cefovecin in the treatment of cats with abscesses and infected wounds was similar to that of cefadroxil. At the final assessment on day 28, 97% (86/89) of cefovecin-treated cats and 91% (80/88) of cefadroxil-treated cats were considered treatment successes. There were no serious adverse events or deaths related to treatment. CONCLUSIONS AND CLINICAL RELEVANCE: 1 SC injection of 8 mg of cefovecin/kg for the treatment of cats with naturally occurring skin infections (wounds and abscesses) was safe and as effective as cefadroxil administered orally at 22 mg/kg, once daily for 14 days.
Assuntos
Abscesso/veterinária , Antibacterianos/uso terapêutico , Doenças do Gato/tratamento farmacológico , Cefalosporinas/uso terapêutico , Infecção dos Ferimentos/veterinária , Abscesso/tratamento farmacológico , Administração Oral , Animais , Antibacterianos/efeitos adversos , Gatos , Cefalosporinas/efeitos adversos , Relação Dose-Resposta a Droga , Feminino , Injeções Subcutâneas/veterinária , Masculino , Testes de Sensibilidade Microbiana/veterinária , Segurança , Resultado do Tratamento , Infecção dos Ferimentos/tratamento farmacológicoRESUMO
OBJECTIVE: To evaluate the efficacy and safety of administration of cefovecin, compared with cefadroxil, for treatment of naturally occurring secondary superficial pyoderma, abscesses, and infected wounds in dogs. DESIGN: Multicenter, randomized, positive-controlled clinical trial. ANIMALS: 235 client-owned dogs. PROCEDURES: Dogs with clinical signs of skin infection confirmed via bacteriologic culture were randomly allocated to receive a single SC injection of cefovecin (8 mg/kg [3.6 mg/lb]) followed by placebo administered PO twice daily for 14 days or cefadroxil (22 mg/kg [10 mg/lb]) administered PO twice daily for 14 days following a placebo injection. Two 14-day treatment courses were permitted. Treatment success was defined as reduction of clinical signs to mild or absent at the final assessment. RESULTS: Clinical efficacy achieved with cefovecin in dogs was equivalent to that observed with cefadroxil. At the final assessment, 14 days following the completion of treatment (on day 28 or 42), 92.4% (109/118) of the cefovecin group and 92.3% (108/117) of the cefadroxil group were treatment successes. There were no serious adverse events or deaths related to treatment. CONCLUSIONS AND CLINICAL RELEVANCE: A single cefovecin injection (8 mg/kg) administered SC, which could be repeated once after 14 days, was safe and effective against naturally occurring skin infections in dogs and as effective as cefadroxil administered PO twice daily for 14 or 28 days.
Assuntos
Abscesso/veterinária , Antibacterianos/uso terapêutico , Cefalosporinas/uso terapêutico , Doenças do Cão/tratamento farmacológico , Foliculite/veterinária , Infecção dos Ferimentos/veterinária , Abscesso/tratamento farmacológico , Animais , Cefadroxila/efeitos adversos , Cefadroxila/uso terapêutico , Cefalosporinas/efeitos adversos , Cães , Feminino , Foliculite/tratamento farmacológico , Masculino , Segurança , Resultado do Tratamento , Infecção dos Ferimentos/tratamento farmacológicoRESUMO
Efficacy and field safety of tulathromycin administered as a single-dose treatment to crossbreed beef calves with undifferentiated bovine respiratory disease (BRD) were evaluated in a multicenter field study conducted at four US feedlots. Two hundred castrated male calves were enrolled at each study site. The treatment groups were physiologic saline (n = 160) given SC at 0.02 ml/kg, tulathromycin (n = 320) given SC at 2.5 mg/kg, and tilmicosin (n = 320) given SC at 10 mg/kg. Nasopharyngeal swabs for bacterial culture were obtained before treatment. The cure rate for calves treated with tulathromycin (78%) and tilmicosin (65%) was significantly (P < or = .0001) higher than that of calves treated with saline (23.8%). The cure rate of calves treated with tulathromycin (78.4%) was significantly (P = .0007) higher than that of calves treated with tilmicosin (64.9%). No adverse events related to tulathromycin were reported. Under the conditions of this study, tulathromycin administered as a single-dose treatment was efficacious in the treatment of undifferentiated BRD.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Animais , Animais Recém-Nascidos , Antibacterianos/administração & dosagem , Bovinos , Dissacarídeos/administração & dosagem , Compostos Heterocíclicos/administração & dosagem , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Masculino , Nasofaringe/microbiologia , Pasteurelose Pneumônica/patologia , Resultado do Tratamento , Tilosina/administração & dosagem , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Estados UnidosRESUMO
Three studies conducted at feedlots in Colorado, Idaho, and Texas examined the comparative efficacy of tulathromycin injectable solution for the treatment of cattle at high risk of developing undifferentiated bovine respiratory disease (BRD). Each study randomly allocated 250 calves to receive tulathromycin at 2.5 mg/kg and 250 calves to receive either tilmicosin at 10 mg/kg (Colorado site) or florfenicol at 40 mg/kg (Idaho and Texas sites) on arrival at the feedlot. Calves were housed by treatment group in pens with 50 calves/pen. Beginning 3 days after antimicrobial treatment, cattle were observed for signs of BRD daily until harvest. In all three studies, the treatment success rates at 28 days after treatment and at harvest were significantly higher (P < or = .013) for cattle treated with tulathromycin than for cattle treated with either tilmicosin or florfenicol. Fewer tulathromycin-treated cattle were removed from the group as "chronics" or "mortalities" at 28 days posttreatment (P < or = .014) in all three studies. Tulathromycin demonstrated superior efficacy compared with tilmicosin and florfenicol when treating groups of high-risk cattle before the onset of signs of BRD.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Bovinos , Dissacarídeos/administração & dosagem , Compostos Heterocíclicos/administração & dosagem , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Masculino , Pasteurelose Pneumônica/etiologia , Pasteurelose Pneumônica/patologia , Recidiva , Fatores de Risco , Índice de Gravidade de Doença , Tianfenicol/administração & dosagem , Tianfenicol/análogos & derivados , Tianfenicol/uso terapêutico , Resultado do Tratamento , Tilosina/administração & dosagem , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Estados UnidosRESUMO
The efficacy of tulathromycin in decreasing the incidence of morbidity and mortality due to bovine respiratory disease (BRD) in 1,239 high-risk cattle was investigated at four US feedlots. Calves not exhibiting clinical signs of BRD received one of three treatments administered subcutaneously in the neck: physiologic saline at 0.02 ml/kg, tulathromycin at 2.5 mg/kg, or tilmicosin at 10 mg/kg. Each treatment group consisted of 413 calves. Calves with clinical signs of BRD and rectal temperatures of 104 degrees F or higher on days 1 through 14 were considered treatment failures (BRD morbidity). Nasopharyngeal swabs from saline-treated morbidities were submitted for isolation and identification of BRD organisms. Respiratory disease morbidity was highest in calves treated with saline and significantly (P < or = .0001) lower in calves administered tulathromycin or tilmicosin. Morbidity from BRD was significantly (P < or = .0001) higher in calves treated with tilmicosin than in calves treated with tulathromycin. Under conditions of this study, tulathromycin, given to calves at high risk of developing BRD, was significantly more effective in reducing BRD morbidity when compared to both saline- and tilmicosin-treated calves.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Bovinos , Dissacarídeos/administração & dosagem , Compostos Heterocíclicos/administração & dosagem , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Masculino , Nasofaringe/microbiologia , Pasteurelose Pneumônica/etiologia , Fatores de Risco , Resultado do Tratamento , Tilosina/administração & dosagem , Tilosina/análogos & derivados , Tilosina/uso terapêuticoRESUMO
The therapeutic efficacy and field safety of tulathromycin were evaluated in stocker calves with undifferentiated bovine respiratory disease (BRD) in three field studies conducted over two consecutive grazing seasons in Nebraska. Eight hundred calves exhibiting clinical signs of BRD and with rectal temperatures of 104 degrees F or higher were treated with tulathromycin (n = 340), florfenicol (n = 240), or tilmicosin (n = 220) and evaluated for approximately 60 days. Florfenicol and tilmicosin were administered as single SC injections according to labeled dosage. Tulathromycin was administered as a single SC injection of 2.5 mg/kg. In all three studies, the cure rate of calves 60 days after treatment with tulathromycin was significantly higher (P < or = .05) than that of calves treated with florfenicol or tilmicosin. Suspected adverse reactions were not reported for any of the study drugs. Tulathromycin proved to be significantly more effective than either florfenicol or tilmicosin in the treatment of BRD in stocker calves.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Bovinos , Dissacarídeos/administração & dosagem , Compostos Heterocíclicos/administração & dosagem , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Masculino , Pasteurelose Pneumônica/patologia , Recidiva , Índice de Gravidade de Doença , Tianfenicol/administração & dosagem , Tianfenicol/análogos & derivados , Tianfenicol/uso terapêutico , Resultado do Tratamento , Tilosina/administração & dosagem , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Estados Unidos , Aumento de PesoRESUMO
Four studies conducted at feedlots in Greeley and Wellington, Colorado; Nebraska; and Texas compared the efficacy of tulathromycin to florfenicol or tilmicosin for the treatment of cattle with undifferentiated bovine respiratory disease (BRD) and subsequent feedlot performance and carcass characteristics. In each study, 100 calves with BRD were treated with tulathromycin given SC at 2.5 mg/kg body weight. At the Greeley, CO, and Nebraska study locations, 100 calves were treated with florfenicol given SC at 40 mg/kg body weight, and at the Wellington, CO, and Texas study locations, tilmicosin was given SC at 10 mg/kg body weight. Cure rate, a derived variable that included assessments of mortality, rectal temperature, and attitude and respiratory scores from day 3 to day 28 and day 3 through harvest, was the primary assessment of BRD efficacy. Cure rates of calves treated with tulathromycin were significantly (P < or = .009) higher than those calves treated with florfenicol. At Wellington, CO, the cure rate of calves treated with tulathromycin was significantly higher (P < or = .018) compared with tilmicosin-treated calves. The differences in cure rates between tulathromycin and tilmicosin treatment groups in the Texas study were not significantly different (P > .05). Tulathromycin was more efficacious in the treatment of undifferentiated BRD compared with florfenicol and, in one study, compared with tilmicosin.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Bovinos , Dissacarídeos/administração & dosagem , Compostos Heterocíclicos/administração & dosagem , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Masculino , Pasteurelose Pneumônica/patologia , Recidiva , Índice de Gravidade de Doença , Tianfenicol/administração & dosagem , Tianfenicol/análogos & derivados , Tianfenicol/uso terapêutico , Resultado do Tratamento , Tilosina/administração & dosagem , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Estados Unidos , Aumento de PesoRESUMO
Tulathromycin, a novel triamilide antimicrobial, was evaluated for treatment of swine respiratory disease (SRD) in field efficacy studies involving 720 pigs in six North American swine herds. In each study, feeder pigs with clinical SRD were randomly assigned in equal numbers to a group treated with tulathromycin given as a single injection at 2.5 mg/kg of body weight or to a saline-treated control group. Four of the studies included a third group treated with ceftiofur sodium for 3 consecutive days at 3 mg/kg of body weight. Pigs were treated on day 0 and evaluated for treatment response on day 7. In each study, 10 or more nontreated pigs and saline-treated pigs that did not respond to treatment underwent necropsies to obtain lung samples that were evaluated for SRD pathogens. The overall cure rate was 46.4% for saline-treated pigs, 71.1% for tulathromycin-treated pigs, and 63.1% for ceftiofur-treated pigs. The cure rate for tulathromycin-treated pigs was significantly higher than for saline-treated pigs (P = .0116). Mortality from SRD occurred in 24 control pigs, seven tulathromycin-treated pigs, and one ceftiofur-treated pig. The mortality rate was significantly lower for both the tulathromycin- and ceftiofur-treated pigs compared with those treated with saline (P = .0148 and P = .0195, respectively). Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Mycoplasma hyopneumoniae, bacteria commonly associated with SRD, were isolated from SRD-affected pigs. Under field conditions, tulathromycin injectable solution given as a single IM dose of 2.5 mg/kg of body weight was safe and effective in the treatment of SRD.
Assuntos
Antibacterianos/uso terapêutico , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Pasteurelose Pneumônica/tratamento farmacológico , Doenças dos Suínos/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Cefalosporinas/administração & dosagem , Cefalosporinas/uso terapêutico , Dissacarídeos/administração & dosagem , Dissacarídeos/farmacologia , Feminino , Bactérias Gram-Negativas/efeitos dos fármacos , Compostos Heterocíclicos/administração & dosagem , Compostos Heterocíclicos/farmacologia , Injeções Intramusculares/veterinária , Masculino , Testes de Sensibilidade Microbiana/veterinária , Mycoplasma hyopneumoniae/efeitos dos fármacos , Pasteurelose Pneumônica/microbiologia , Pasteurelose Pneumônica/patologia , Índice de Gravidade de Doença , Suínos , Doenças dos Suínos/microbiologia , Doenças dos Suínos/patologia , Resultado do Tratamento , Estados UnidosRESUMO
OBJECTIVE: To compare concentrations of danofloxacin, enrofloxacin, and ciprofloxacin in plasma and respiratory tissues of calves treated after challenge with Mannheimia haemolytica. ANIMALS: 75 calves. PROCEDURE: 24 hours after challenge with M. haemolytica, 72 calves with clinical signs of respiratory tract disease were randomly assigned to 1 of 12 equal treatment groups. Three nonchallenged, nontreated calves formed a control group. Challenged calves were treated with danofloxacin (6 and 8 mg/kg, SC) and enrofloxacin (8 mg/kg, SC) once. At 1, 2, 6, and 12 hours after treatment, 6 calves from each treatment group were euthanatized. Antimicrobial drug concentrations were assayed in various specimens. Peak plasma concentration (Cmax)-to-minimum inhibitory concentration (MIC; Cmax-to-MIC) ratios and the area under the concentration versus time curve over a 12-hour period-to-MIC ratios (AUC(12h)-to-MIC) were calculat-ed. RESULTS: Danofloxacin and enrofloxacin had MICs of 0.03 microg/mL for the M. haemolytica challenge isolate. Danofloxacin administered at doses of 6 and 8 mg/kg resulted in numerically higher geometric mean concentrations of danofloxacin in plasma and all respiratory tissues than geometric mean concentrations of enrofloxacin after treatment with enrofloxacin. Geometric mean concentrations of enrofloxacin were numerically higher than geometric mean concentrations of ciprofloxacin metabolite in plasma and almost all respiratory tissues. Danofloxacin and enrofloxacin achieved Cmax-to-MIC ratios >10 and AUC(12h)-to-MIC ratios >125 hours. CONCLUSIONS AND CLINICAL RELEVANCE: When used to treat pneumonic pasteurellosis in calves, danofloxacin and enrofloxacin can be expected to deliver concentration-dependent bactericidal activity against M. haemolytica, the bacteria most commonly associated with bovine respiratory tract disease.
Assuntos
Anti-Infecciosos/farmacocinética , Fluoroquinolonas/farmacocinética , Mannheimia haemolytica/patogenicidade , Pasteurelose Pneumônica/metabolismo , Quinolonas/farmacocinética , Animais , Lavagem Broncoalveolar/veterinária , Líquido da Lavagem Broncoalveolar/química , Bovinos , Cromatografia Líquida de Alta Pressão/veterinária , Ciprofloxacina/farmacocinética , Enrofloxacina , Pulmão/metabolismo , Pulmão/microbiologia , Masculino , Testes de Sensibilidade Microbiana/veterinária , Pasteurelose Pneumônica/microbiologiaRESUMO
The pharmacokinetics of the new triamilide antibiotic tulathromycin was investigated in two cattle studies. Following a single subcutaneous injection, the drug was rapidly absorbed and bioavailability was excellent. High and persistent levels of the drug in lung tissue were observed as well. These attributes are advantageous for an antimicrobial drug indicated for the treatment of bacterial and mycoplasmal respiratory diseases in cattle.
Assuntos
Anti-Infecciosos/farmacocinética , Bovinos/metabolismo , Dissacarídeos/farmacocinética , Compostos Heterocíclicos/farmacocinética , Pulmão/metabolismo , Animais , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/sangue , Área Sob a Curva , Dissacarídeos/administração & dosagem , Dissacarídeos/sangue , Feminino , Compostos Heterocíclicos/administração & dosagem , Compostos Heterocíclicos/sangue , Injeções Intravenosas/veterinária , Injeções Subcutâneas/veterinária , MasculinoRESUMO
OBJECTIVE: To examine effects of danofloxacin and tilmicosin on continuously recorded body temperature in beef calves with pneumonia experimentally induced by inoculation of Mannheimia haemolytica. ANIMALS: 41 Angus-cross heifers (body weight, 160 to 220 kg) without a recent history of respiratory tract disease or antimicrobial treatment, all from a single ranch. PROCEDURE: Radiotransmitters were implanted intravaginally in each calf. Pneumonia was induced intrabronchially by use of logarithmic-phase cultures of M. haemolytica. At 21 hours after inoculation, calves were treated with saline (0.9% NaCl) solution, danofloxacin, or tilmicosin. Body temperature was monitored from 66 hours before inoculation until 72 hours after treatment. Area under the curve (AUC) of the temperature-time plot and mean temperature were calculated for 3-hour intervals and compared among treatment groups. RESULTS: The AUCs for 3-hour intervals did not differ significantly among treatment groups for any of the time periods. Analysis of the mean temperature for 3-hour intervals revealed significantly higher temperatures at most time periods for saline-treated calves, compared with temperatures for antimicrobial-treated calves; however, we did not detect significant differences between the danofloxacin- and tilmicosin-treated calves. The circadian rhythm of temperatures before exposure was detected again approximately 48 hours after bacterial inoculation. CONCLUSIONS AND CLINICAL RELEVANCE: Danofloxacin and tilmicosin did not differ in their effect on mean body temperature for 3-hour intervals but significantly decreased body temperature, compared with body temperature in saline-treated calves. Normal daily variation in body temperature must be considered in the face of respiratory tract disease during clinical evaluation of feedlot cattle.